Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ASK: "THE LAST DON" OF MOMENTUM TRADES -- Ignore unavailable to you. Want to Upgrade?

To: LANCE B who wrote (2360)	1/6/1999 8:19:00 AM
From: MoneyMade	Respond to of 15987

Accumulate WOOD, COGX news is still fresh\|Corgenix Receives FDA Clearance to Market Four New Products for the Diagnosis and Risk Assessment of Blood Clotting Disorders PR Newswire - January 05, 1999 07:16 DENVER, Jan. 5 /PRNewswire/ -- Corgenix Medical Corporation (OTC Bulletin Board: COGX) announced today that it has received clearance to market four new products for the diagnosis and risk assessment of blood clotting disorders (thrombosis) from the US Food and Drug Administration (FDA). Three of the new test kits cleared by the FDA detect antibodies to Beta 2 Glycoprotein I which are indicators of increased risk for developing clinical thrombosis (blood clots) as seen in patients with deep venous thrombosis, heart attacks and strokes. These assays are more specific for thrombosis and represent a step forward in the diagnosis and management of blood clotting disease. A fourth test kit (Monoclonal Free Protein S Antigen Test Kit) also cleared by the FDA measures Free Protein S which is an important physiological regulator of coagulation. A deficiency of Protein S may lead to serious thrombotic (blood clot) events. The use of a monoclonal antibody specific for Free Protein S provides a more specific, rapid and convenient laboratory test. The American Thrombosis Association estimates between 5 to 20 million cases of blood clot-related diseases in the U.S. each year. Approximately 1.7 million Americans suffer heart attacks or strokes annually, resulting in 800,000 deaths. The frequency of venous thrombosis in the general population has been estimated to be approximately 1 in 1,000 individuals per year. Douglass T. Simpson, President of Corgenix said, "With the clearance from the FDA to market these coagulation assays, the company will immediately offer these test kits to clinical laboratories worldwide to continue building a leadership role in the growing vascular disease testing market." Corgenix Medical Corporation is based in metropolitan Denver and is focused on the development and promotion of specialized diagnostic test kits for vascular diseases, immunological disorders, bone diseases and joint diseases. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. Statements in this release that are not strictly historical are "forward- looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, and should be considered as subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. For more information, contact Chris Wolfe, investor relations coordinator of Corgenix at (303) 457-4345 ext.147. SOURCE Corgenix Medical Corporation /CONTACT: Chris Wolfe, Investor Relations Coordinator of Corgenix, 303-457-4345, ext.147/ /Web site: corgenix.com (COGX)